Rua Bioscience today announces that Cann Group has given 12 months’ notice to terminate its existing supply contract with Rua Bioscience.
In response to Cann’s decision, Rua Bioscience has engaged legal advice to consider options.
There have been recent quality issues with Cann’s export products, which had already prompted Rua Bioscience to proactively explore alternative supply partnerships.
In the last 12 months, Rua has placed emphasis on securing multiple additional supply pathways with particular emphasis on cultivating our unique genetics in Europe and Australia. We now have more surety that we can consistently supply patients in our key markets of Germany, Australia and New Zealand.
“While we appreciate the history we have had with Cann, we are committed to ensuring the continuity of our operations and maintaining the highest standards in product quality” said Paul Naske, CEO at Rua Bioscience. “
The new supply partnerships will improve supply chain effectiveness and contribute to the overall growth and success of the company.
But the stock exchange operator's revenue was up.
To join your company account for BusinessDesk and enjoy full access, enter your email and we’ll send you details